Faculty

Alexis Ogdie, MD, MSCE

Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania

Department: Medicine

Graduate Group Affiliations

Graduate Group in Epidemiology and Biostatistics

Contact information

3400 Spruce Street
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283

Office: 215-662-2454
Fax: 215-662-4500

Education
BS
University of Minnesota, 2002.
MD
Georgetown University School of Medicine, 2006.
MSCE
University of Pennsylvania, 2012.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

Psoriatic Arthritis, Ankylosing Spondylitis, Spondyloarthropathies, Other Inflammatory Arthritis (e.g. Rheumatoid Arthritis)

Description of Research Expertise

Psoriatic Arthritis, Axial Spondyloarthritis, Epidemiology, Pharmacoepidemiology

Selected Publications

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová E, Morita A, Ruderman EM, Plewinski M, Wang K, Sardinas C, Vritzali E, Vaile J, Deodhar A.: Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. Arthritis Rheumatol Jul 2026.

Pérez-Chada LM, Garfinkel V, Childs BA, Bedapudi A, Woodbury M, Zhang AJ, Ruderman E, Fernandez AP, Mease P, Siegel E, Haberman R, Gladman DD, Reddy SM, Ogdie A, Scher JU, Stidham RW, Merola JF.: Artificial intelligence versus experts: Navigating challenging cases in psoriatic disease. J Invest Dermatol May 2026.

Ramiro S, Gaillez C, Kiltz U, Gensler LS, Pisal C, Braun J, Ogdie A.: No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. Arthritis Res Ther Apr 2026.

Nock MR, Ahn S, Leonard CE, Ogdie A, Cohen JM.: Ambient Temperature and Psoriatic Arthritis Odds Among Patients With Psoriasis: A Cross-sectional Analysis. J Psoriasis Psoriatic Arthritis Apr 2026.

Romich E, Ogdie A, Stephens-Shields A, Merkel PA, Assassi S, Bernstein EJ, Bujor A, Castelino FV, Chung L, Evnin LB, Frech TM, Gordon JK, Griffith M, Hant FN, Harding ML, Hummers LK, Khanna D, Lakin KS, Lebiedz-Odrobina DJ, Luo Y, Makol A, Mayes MD, McMahan ZH, Molitor J, Moore DF, Paik J, Richardson C, Skaug B, Shah AA, Shah A, Steen V, VanBuren JM, Volkmann ER, Zahn C, Sandorfi N; CONQUER Investigators.: Discordance between patient and physician global assessments in early systemic sclerosis. Arthritis Care Res (Hoboken) Apr 2026.

Baker JF, Wysham KD, Quinones M, England BR, Jin K, Olave M, Wetzel S, Gillcrist RL, Lavery C, Keller N, Kramer B, Ateh B, Brubeck H, White DK, Ogdie A, Xiao R, Neogi T, Scanzello CR.: Behavioral Incentives for Exercise and Intra-Articular Corticosteroids for Knee Osteoarthritis: Results from a Factorially Designed Pragmatic Randomized Clinical Trial. Arthritis Rheumatol Apr 2026.

Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N.: Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe. Rheumatology (Oxford) 65: keag106, Mar 2026.

Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A.: Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol Mar 2026.

Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ.: Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data. Adv Ther Mar 2026.

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB.: Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study. Arthritis Rheumatol Feb 2026.